Form 4: Nektar Therapeutics CEO Howard W. Robin Sells Shares to Cover Tax Obligations
SEC Form 4 Filing
Nektar Therapeutics CEO Howard W. Robin sold 14,881 shares of common stock on August 19, 2024, to cover tax withholding obligations related to vesting RSUs.
Summary
- On August 19, 2024, Howard W. Robin, the President and CEO of Nektar Therapeutics, sold 14,881 shares of the company's common stock.
- The sale was executed to cover required tax withholding obligations associated with the vesting of restricted stock units (RSUs).
- The shares were sold at a weighted average price of $1.28, with individual transactions ranging from $1.24 to $1.32.
- Following the transaction, Robin directly owns 848,358 shares of Nektar Therapeutics common stock and indirectly owns 410 shares through a spouse.
Sentiment
Score: 5
Explanation: The document describes a routine transaction (selling shares to cover taxes on vested RSUs), so the sentiment is neutral.
Industry Context
This is a routine transaction related to executive compensation and tax obligations. It is common for executives to sell shares to cover taxes when RSUs vest.
Stakeholder Impact
- The sale of shares by the CEO could have a minor negative impact on shareholder sentiment, although it is a routine transaction.
Key Dates
| Date | Description |
|---|---|
| 08/19/2024 | Date of stock sale transaction. |
| 08/20/2024 | Date of signature on the SEC Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.